Cooperative Agreement R43CA221511

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $799,962 to Tripill Biotechnology, Corp. to develop radiolabeled PSMA agents with low salivary gland uptake for improved prostate cancer imaging and therapy. The key products and services to be delivered include: Constructing PSMA derivative compounds, such as NOTA-UNC-PSMA2, that can selectively reduce salivary gland uptake while maintaining high tumor uptake in prostate...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $571,271 to the University of Texas Health Science Center at Houston (UTHealth) to develop a targeted therapy for the treatment of metastatic castration-resistant prostate cancer (MCRPC). The goal is to create a non-radioactive, PSMA-targeted drug conjugate that uses the microtubule inhibitor monomethyl auristatin E (MMAE) to suppress microtubule dynamics and treat MCRPC. This work aims...

This Project Grant award of $353,009.00 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Paramita Therapeutics Inc. (UEI: MRDLCLW1SH57) will support the development of novel multivalent PSMA-targeted taxane-conjugates for the treatment of bone metastases in prostate cancer. The project aims to synthesize and evaluate these targeted drug conjugates, which are expected to improve the water solubility and selective targeting of taxane chemotherapies to prostate cancer...

This Project Grant award, valued at $684,107 and funded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), supports research to integrate circulating tumor cell and nuclear imaging biomarkers to assess the response and resistance to Lutetium-177-PSMA (LUPSMA) radiopharmaceutical therapy in advanced prostate cancer patients. The award was granted to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), a renowned...

This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $185,760 to The Regents of the University of California, San Francisco to enhance prostate cancer treatment outcomes through a novel combination therapy approach. The project aims to develop a single antibody-drug conjugate that delivers both a cytotoxic drug (monomethyl auristatin E) and a radioactive isotope (actinium-225) directly to cancer cells. This synergistic...

The National Cancer Institute (NCI), under the federal Cancer Treatment Research program (CFDA 93.395), awarded Isoprene Pharmaceuticals Inc. a $1,022,522 Project Grant on June 4, 2025 to support the "Development of VNPP433-3beta as Novel Therapeutic for All Stages of Prostate Cancer." The project aims to develop Isoprene's lead compound VNPP433-3beta and related analogs as novel, orally bioavailable treatments that can simultaneously target multiple critical oncogenic pathways in...

This federal Project Grant award of $545,078, funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), is supporting research at The Johns Hopkins University to investigate the use of radiopharmaceutical therapy in combination with inhibition of glutamine metabolism as a novel therapeutic strategy for prostate cancer and renal cell carcinoma. The project aims to systematically evaluate the effect of prostate-specific membrane antigen (PSMA)-based radiopharmaceutical...

The Department of the Army Medical Command awarded a $685,497 Project Grant to the Regents of the University of California, San Francisco through the Military Medical Research and Development program. The grant will fund a research project from July 2022 through July 2025 to develop GRANZYME B PET imaging as a novel method to assess T-cell activation in response to 177LU-PSMA-617 priming in metastatic castration-resistant prostate cancer. The Military Medical Research and Development program...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $602,361 to Yale University to develop deep learning-based predictive models for personalizing dosimetry and treatment planning for prostate cancer patients receiving 177Lu-PSMA radiopharmaceutical therapy (RPT). The key products and services to be delivered include: Building predictive models using pre-treatment PSMA-PET and during-treatment PSMA-SPECT imaging data, as well as clinical...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $404,972 to the University of California, Los Angeles (UCLA) to conduct research on overcoming radiopharmaceutical therapy resistance in prostate cancer. The research aims to investigate how the tumor microenvironment, specifically the expression of the ENPP1 enzyme, impacts the efficacy of PSMA-targeting radiopharmaceutical therapy. The project will utilize isogenic prostate...